Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005664809
Mon, 08.12.2025
Evotec SE
All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November
Agreement includes approximately US$ 350 m in cash for Just – Evotec Biologics manufacturing site in Toulouse and upfront technology license fees to Evotec’s continuous manufacturing platform
In additio [ … ]
Thu, 04.12.2025
Evotec SE
Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndrome
Milestone payment to Evotec expected upon first dosing of first study participant in early 2026
Hamburg, Germany, 04 December 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 56 [ … ]
Wed, 12.11.2025
Evotec SE
Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations
FDA clearance of IND application triggered a US$ 5 m milestone payment to Evotec
Hamburg, Germany, 12 November 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WK [ … ]
Wed, 05.11.2025
Evotec SE
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand; Just – Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerating growth on non-Sandoz / non-DOD business
Strong scientific advancements of co-developed asset pipeline: Expecting up to four mo [ … ]
Tue, 04.11.2025
Evotec SE
In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties on portfolio of up to 10 biosimilar molecules
Transaction showcases Evotec’s unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing techn [ … ]
Wed, 29.10.2025
Evotec SE
Hamburg, Germany, 29 October 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) will announce its interim statement for the first nine months 2025 on Wednesday, 05 November 2025.
The Company is going to hold a conference call to discuss the results as well as provide an update [ … ]
Mon, 27.10.2025
Evotec SE
Advances made in preclinical pipeline addressing neurodegenerative diseases
Evotec receives US$ 25 m payment to support continued progression of joint programs
Hamburg, Germany, 27 October 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) today announced t [ … ]
Wed, 13.08.2025
Evotec SE
Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions
Reporting segment formerly known as Shared R&D renamed to Discovery & Preclinical Development (“D&PD”) to better reflect strategic focus
Group revenues of € 371.2 m (-5%); D&PD (-11%) continu [ … ]
Wed, 06.08.2025
Evotec SE
Hamburg, Germany, 06 August 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) will announce its half-year interim report for the first six months of 2025 on Wednesday, 13 August 2025.
The Company is going to hold a conference call to discuss the results as well as provide an u [ … ]
Wed, 30.07.2025
Evotec SE
Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just – Evotec Biologics EU in Toulouse to Sandoz
Under the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines using Just – Evotec Biologics’ advanced continuous manufacturing technology
[ … ]
